ArticleBMC nephrology2022

A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease.

Gregory Mader et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.